Semaglutide biosimilar (Zhuhai United Laboratories)

This study used semaglutide injection developed by United Biotech (Zhuhai Hengqin) Co., Ltd. and semaglutide injection (trade name: Novo Nordisk®) to treat patients with type 2 diabetes for 32 weeks, and compared the decrease and target rate of glycated hemoglobin and fasting blood glucose before and after treatment, as well as changes in body weight; at the same time, the incidence of hypoglycemia, gastrointestinal events and other related safety indicators and immunogenicity indicators were compared between the two groups, as well as the similarity of pharmacokinetics between the two groups. The main purpose is to evaluate the similarity of the effectiveness and safety of semaglutide injection developed by United Biotech and Novo Nordisk® in patients with type 2 diabetes.

The primary objective is to investigate the pharmacokinetic characteristics of semaglutide injection and to compare the pharmacokinetic similarity of a single subcutaneous injection of semaglutide injection (experimental drug) with the original product "Novotai®" (control drug) in healthy Chinese adult subjects. The secondary objective is to evaluate the safety and preliminary immunogenicity of semaglutide injection.